S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:APEN

Apollo Endosurgery - APEN Stock Forecast, Price & News

$10.02
+0.01 (+0.10%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.00
$10.04
50-Day Range
$4.93
$10.14
52-Week Range
$3.49
$10.30
Volume
553,323 shs
Average Volume
354,638 shs
Market Capitalization
$417.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25

Apollo Endosurgery MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
12.3% Upside
$11.25 Price Target
Short Interest
Bearish
2.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.24mentions of Apollo Endosurgery in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

900th out of 1,027 stocks

Surgical & Medical Instruments Industry

88th out of 101 stocks

APEN stock logo

About Apollo Endosurgery (NASDAQ:APEN) Stock

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive APEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

APEN Stock News Headlines

Apollo Endosurgery to be Acquired by Boston Scientific
Apollo Endosurgery, Inc. (APEN)
Apollo Tyres Ltd (APLO)
MIMEDX Announces Leadership Transition
See More Headlines
Receive APEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

APEN Company Calendar

Last Earnings
10/31/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APEN
Employees
202
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.25
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+12.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-24,680,000.00
Pretax Margin
-56.26%

Debt

Sales & Book Value

Annual Sales
$62.99 million
Book Value
$1.55 per share

Miscellaneous

Free Float
34,431,000
Market Cap
$417.17 million
Optionable
Not Optionable
Beta
2.39

Key Executives

  • Mr. Charles S. McKhann (Age 53)
    CEO, Pres & Director
    Comp: $963.53k
  • Mr. Jeffrey G. BlackMr. Jeffrey G. Black (Age 53)
    CFO, Sec. & Treasurer
    Comp: $524.02k
  • Mr. John J. Molesphini (Age 64)
    Exec. VP of Operations
    Comp: $502.58k
  • Dr. Sergey Kantsevoy M.D.
    Co-Founder and Innovation Partner
  • Mr. Anthony Kalloo M.D.
    Co-Founder and Innovation Partner
  • Dr. Robert Hawes M.D.
    Co-Founder and Innovation Partner
  • Dr. Peter Benjamin Cotton M.D.
    Co-Founder and Innovation Partner
  • Dr. Christopher J. Gostout M.D. (Age 71)
    Co-Founder & Chief Medical Officer
  • Mr. Sydney Chung M.D.
    Co-Founder and Innovation Partner
  • Dr. Pankaj Jay Pasricha FACP
    M.D., MBBS, Co-Founder













APEN Stock - Frequently Asked Questions

Should I buy or sell Apollo Endosurgery stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APEN shares.
View APEN analyst ratings
or view top-rated stocks.

What is Apollo Endosurgery's stock price forecast for 2023?

3 analysts have issued 1 year price objectives for Apollo Endosurgery's stock. Their APEN share price forecasts range from $10.00 to $13.00. On average, they expect the company's share price to reach $11.25 in the next year. This suggests a possible upside of 12.3% from the stock's current price.
View analysts price targets for APEN
or view top-rated stocks among Wall Street analysts.

How have APEN shares performed in 2022?

Apollo Endosurgery's stock was trading at $8.43 at the start of the year. Since then, APEN shares have increased by 18.9% and is now trading at $10.02.
View the best growth stocks for 2022 here
.

When is Apollo Endosurgery's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our APEN earnings forecast
.

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery, Inc. (NASDAQ:APEN) announced its quarterly earnings results on Sunday, October, 31st. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. The biotechnology company had revenue of $16.35 million for the quarter, compared to the consensus estimate of $16.20 million. Apollo Endosurgery had a negative net margin of 56.74% and a negative trailing twelve-month return on equity of 78.73%. During the same period last year, the business posted ($0.11) EPS.

What guidance has Apollo Endosurgery issued on next quarter's earnings?

Apollo Endosurgery issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $75.00 million-$76.00 million, compared to the consensus revenue estimate of $73.95 million.

What other stocks do shareholders of Apollo Endosurgery own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Who are Apollo Endosurgery's major shareholders?

Apollo Endosurgery's stock is owned by many different retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (6.80%), Gagnon Securities LLC (4.29%), Vanguard Group Inc. (3.27%), Silverarc Capital Management LLC (2.79%), Russell Investments Group Ltd. (2.34%) and Parkman Healthcare Partners LLC (1.58%). Insiders that own company stock include Chas Mckhann, Cpmg Inc, David Pacitti, Jeffrey G Black, John R Barr, Neil Gagnon and R Kent Mcgaughy Jr.
View institutional ownership trends
.

How do I buy shares of Apollo Endosurgery?

Shares of APEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $10.02.

How much money does Apollo Endosurgery make?

Apollo Endosurgery (NASDAQ:APEN) has a market capitalization of $417.13 million and generates $62.99 million in revenue each year. The biotechnology company earns $-24,680,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Apollo Endosurgery have?

The company employs 202 workers across the globe.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The official website for the company is www.apolloendo.com. The biotechnology company can be reached via phone at (512) 279-5100, via email at investor-relations@apolloendo.com, or via fax at 858-678-0900.

This page (NASDAQ:APEN) was last updated on 12/8/2022 by MarketBeat.com Staff